Stockreport

ChemoCentryx And Aurinia In Focal Segmental Glomerulosclerosis: Strength In Numbers [Seeking Alpha]

ChemoCentryx, Inc.  (CCXI) 
Last chemocentryx, inc. earnings: 3/10 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.chemocentryx.com
PDF ChemoCentryx And Aurinia In Focal Segmental Glomerulosclerosis: Strength In Numbers Summary CCX140 is a CCR2 chemokine receptor antagonist in two Phase 2 clinical trials [Read more]